GETI.B

201.3

-0.79%↓

AMBEA

123.6

-0.56%↓

ARJOB

27.04

-1.31%↓

MSON.B

10.85

+1.88%↑

ORX

25.45

-3.42%↓

GETI.B

201.3

-0.79%↓

AMBEA

123.6

-0.56%↓

ARJOB

27.04

-1.31%↓

MSON.B

10.85

+1.88%↑

ORX

25.45

-3.42%↓

GETI.B

201.3

-0.79%↓

AMBEA

123.6

-0.56%↓

ARJOB

27.04

-1.31%↓

MSON.B

10.85

+1.88%↑

ORX

25.45

-3.42%↓

GETI.B

201.3

-0.79%↓

AMBEA

123.6

-0.56%↓

ARJOB

27.04

-1.31%↓

MSON.B

10.85

+1.88%↑

ORX

25.45

-3.42%↓

GETI.B

201.3

-0.79%↓

AMBEA

123.6

-0.56%↓

ARJOB

27.04

-1.31%↓

MSON.B

10.85

+1.88%↑

ORX

25.45

-3.42%↓

Home・Akciju saraksts・Vivesto AB

Vivesto AB

Atvērts

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Galvenie mērījumi
By Trading Economics
Ienākumi	2.3M -7.2M
EPS	-0.013
Darbinieki	4
EBITDA	-7.1M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 27. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-25M 54M
Iepriekšējā atvēršanas cena	0
Iepriekšējā slēgšanas cena	0

Vivesto AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. febr. 23:55 UTC

Tirgus saruna

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026. g. 22. febr. 23:53 UTC

Tirgus saruna

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026. g. 22. febr. 23:51 UTC

Tirgus saruna

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026. g. 22. febr. 23:35 UTC

Tirgus saruna

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026. g. 22. febr. 23:21 UTC

Peļņas

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026. g. 22. febr. 23:20 UTC

Peļņas

Nickel Industries 2025 Operating Profit US$126.4 Million

2026. g. 22. febr. 23:19 UTC

Peļņas

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026. g. 22. febr. 23:19 UTC

Peļņas

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 23:18 UTC

Peļņas

Nickel Industries Won't Pay a Final Dividend

2026. g. 22. febr. 23:16 UTC

Peļņas

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026. g. 22. febr. 21:35 UTC

Peļņas

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026. g. 22. febr. 21:34 UTC

Peļņas

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026. g. 22. febr. 21:33 UTC

Peļņas

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol Final Dividend A$0.60/Share

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Revenue A$31.37 Billion, Down 10%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026. g. 22. febr. 21:28 UTC

Peļņas

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026. g. 21. febr. 14:31 UTC

Iegādes, apvienošanās, pārņemšana

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026. g. 21. febr. 05:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Salīdzinājums

Cenas izmaiņa

Vivesto AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.